Analyst Group

Analyst Group Comment on Circio's Research Collaboration with Tcelltech

Källa: MFN
Neutral

Sammanfattning

Circio Holding ASA ingår ett forskningssamarbete med Tcelltech GmbH för att kombinera deras teknologier för utveckling av T-cellsterapier. Samarbetet syftar till att adressera leverans- och uttrycksproblem inom in vivo CAR-T och TCR-T. Inga finansiella villkor har offentliggjorts.

Analys

Samarbetet med Tcelltech är tekniskt logiskt och kompletterar Circios befintliga teknologiplattform för in vivo cellterapier. Genom att kombinera Tcelltechs icke-virala vektorplattform med Circios circVec kan de adressera kritiska flaskhalsar inom leverans och uttryckshållbarhet. Programmet befinner sig dock i ett tidigt prekliniskt skede utan offentliggjorda finansiella villkor, vilket innebär att det representerar en långsiktig option snarare än en omedelbar värdedrivare.

Insikter

  • • Samarbetet adresserar komplementära flaskhalsar inom in vivo CAR-T/TCR-T.
  • • Cellterapisegmentet utgör en långsiktig option snarare än en omedelbar värdedrivare.
  • • Samarbetet adderar en trovärdig partner till circVecs leveransnätverk.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 24th of June 2026, a research collaboration with Tcelltech GmbH (”Tcelltech”), a Mannheim-based biotechnology company, to combine circVec with Tcelltech’s non-viral, non-integrating, episomal nanoSMAR DNA vector platform for next-generation engineered T-cell therapies, including in vivo CAR-T and TCR-T. The program runs in stages: an initial proof-of-concept phase comparing how strongly and how durable the technology combination drives gene expression in primary human T cells, followed by a functional phase in which CD19-directed CAR T cells are generated and assessed for their ability to kill tumor cells. No financial terms are disclosed.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 24th of June 2026, a research collaboration with Tcelltech GmbH (”Tcelltech”), a Mannheim-based biotechnology company, to combine circVec with Tcelltech’s non-viral, non-integrating, episomal nanoSMAR DNA vector platform for next-generation engineered T-cell therapies, including in vivo CAR-T and TCR-T. The program runs in stages: an initial proof-of-concept phase comparing how strongly and how durable the technology combination drives gene expression in primary human T cells, followed by a functional phase in which CD19-directed CAR T cells are generated and assessed for their ability to kill tumor cells. No financial terms are disclosed.

In summary, Analyst Group views the Tcelltech collaboration as a technically coherent addition to Circio’s in vivo cell therapy portfolio. The non-viral, high-cargo nanoSMAR format addresses the delivery problem, while circVec addresses the expression-durability problem. These are complementary bottlenecks that together could form the basis of a differentiated in vivo CAR-T/TCR-T approach. That said, the program remains at an early preclinical stage with no disclosed financial terms. The cell therapy track also continues to represent a longer-dated optionality layer rather than a near-term value driver. On balance, Analyst Group assesses that the collaboration adds another credible partner to circVec’s delivery network and incrementally supports the platform’s licensing appeal.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.